Welcome to

KaNDy
Therapeutics

Developing a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening

A unique approach

Progressing our unique once daily dual mechanism neurokinin antagonist NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. NT-814 has successfully completed a Phase 2a proof of concept study that demonstrate its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening. Preparations are underway for a multi-country Phase 2b study with NT-814 in this anchor Women’s Health Indication, starting in Q4 2018.
Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt